Recursion Pharmaceuticals (RXRX) is up 14.4% today. Here is some analysis on what might have caused this price movement. ([ir.recursion.com](https://ir.recursion.com/news-releases/news-release-details/recursion-announces-200-million-oversubscribed-follow-offering?utm_source=openai))
Analysis: The rally appears tied to a bundle of positive updates released on October 15, 2026, led by Sanofi exercising an option on a collaboration candidate, fresh clinical data across Recursion’s pipeline, and a $200 million financing backed by large healthcare investors. While stock offerings often pressure biotech shares, traders may be focusing on the added cash runway, outside validation from Sanofi, and signs of progress in key drug programs. ([ir.recursion.com](https://ir.recursion.com/news-releases/news-release-details/recursion-announces-200-million-oversubscribed-follow-offering?utm_source=openai))
Details:
Sources:
Recursion Pharmaceuticals, SEC, Nasdaq
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$RXRX Insider Trading Activity
$RXRX insiders have traded $RXRX stock on the open market 14 times in the past 6 months. Of those trades, 0 have been purchases and 14 have been sales.
Here’s a breakdown of recent trading of $RXRX stock by insiders over the last 6 months:
- BLAKE BORGESON has made 0 purchases and 6 sales selling 210,000 shares for an estimated $814,200.
- CHRISTOPHER GIBSON has made 0 purchases and 3 sales selling 120,000 shares for an estimated $412,400.
- NAJAT KHAN (CEO and President) has made 0 purchases and 2 sales selling 45,996 shares for an estimated $163,281.
- ROBERT HERSHBERG sold 25,000 shares for an estimated $125,000
- NAMANDJE BUMPUS has made 0 purchases and 2 sales selling 8,349 shares for an estimated $28,128.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$RXRX Hedge Fund Activity
We have seen 167 institutional investors add shares of $RXRX stock to their portfolio, and 133 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 7,112,385 shares (+16.5%) to their portfolio in Q2 2026, for an estimated $26,102,452
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 4,138,286 shares (+inf%) to their portfolio in Q2 2026, for an estimated $15,187,509
- UBS GROUP AG added 3,845,865 shares (+75.4%) to their portfolio in Q2 2026, for an estimated $14,114,324
- LINGOTTO INVESTMENT MANAGEMENT LLP removed 3,675,077 shares (-62.5%) from their portfolio in Q2 2026, for an estimated $13,487,532
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 3,263,269 shares (-81.1%) from their portfolio in Q2 2026, for an estimated $11,976,197
- RENAISSANCE TECHNOLOGIES LLC removed 2,400,605 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $8,810,220
- GOLDMAN SACHS GROUP INC removed 2,147,803 shares (-35.4%) from their portfolio in Q2 2026, for an estimated $7,882,437
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$RXRX Price Targets
Multiple analysts have issued price targets for $RXRX recently. We have seen 3 analysts offer price targets for $RXRX in the last 6 months, with a median target of $8.0.
Here are some recent targets:
- Vikram Purohit from Morgan Stanley set a target price of $5.5 on 05/14/2026
- Gil Blum from Needham set a target price of $8.0 on 05/07/2026
- Priyanka Grover from JP Morgan set a target price of $10.0 on 04/30/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
